Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
272 Results for "
CDK-9
" in MedChemExpress (MCE) Product Catalog:
Products (272)
272 Results for "CDK-9" in MCE Product Catalog:
Cat. No.: HY-100950R
CAS No.: 1042735-18-1
Target:
Research Areas:
ABC1183 (Standard) is the analytical standard of ABC1183 (HY-100950). This product is intended for research and analytical applications. ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities .
Cat. No.: HY-W093149
CAS No.: 40248-63-3
Cat. No.: HY-123034
CAS No.: 1189558-88-0
Target:
Research Areas:
CDKI-83 is a potent CDK9 and CDK1 inhibitor with Ki values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI50<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .
Cat. No.: HY-156084
CAS No.: 2809353-52-2
LL-K9-3 is a selective CDK9-cyclin T1 HyT degrader, with DC50 values of 0.662 μM and 0.589 μM for CDK9 and Cyclin T1, respectively. LL-K9-3 lacks an E3 ligand moiety and induces polyubiquitination and proteasome-mediated synchronous degradation of CDK9 and cyclin T1 via a hydrophobic tag-mediated mechanism. LL-K9-3 downregulates the protein levels of androgen receptor (AR) and c-Myc, and exhibits antiproliferative and pro-apoptotic (apoptosis) activity in prostate cancer cells. LL-K9-3 can be used in studies related to prostate cancer .
Cat. No.: HY-131063
CAS No.: 2414373-55-8
CDK6/9-IN-1 (compound 66) is an orally active active and dual CDK 6 and CDK 9 inhibitor, with IC50 values of 40.5 nM and 39.5 nM for CDK6 anmd CDK9, respectively .
Cat. No.: HY-178861
Target:
Research Areas:
dCDK9-202 is a CDK9 PROTAC degrader with a DC50 of 3.5 nM. dCDK9-202 induces CDK9 degradation via the ubiquitin-proteasome system. dCDK9-202 inhibits the growth of cancer cells in vitro and suppresses tumor growth in mouse xenograft models. dCDK9-202 is applicable for cancer-related research .
Cat. No.: HY-111537
CAS No.: 1333468-05-5
Target:
Research Areas:
rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.
Cat. No.: HY-119831
CAS No.: 71294-60-5
Target:
NF-κB CDK PPAR Akt mTOR LXR Reactive Oxygen Species (ROS) Apoptosis Wnt Interleukin Related p38 MAPK ERK JNK
Research Areas:
Rohitukine is an orally active CDK9/T1 inhibitor with an IC50 of 0.3 μM. Rohitukine blocks ATP binding sites of CDK2/A and CDK9/T1, suppresses PPARγ, AKT, mTOR, C/EBPα, SREBP-2, and NF-κB signaling, and increases hepatic LXRα expression. Rohitukine induces S-phase cell cycle arrest, ROS generation, apoptosis, and exhibits anti-inflammatory activity. Rohitukine can be used for the research of leukemia, pancreatic cancer, prostate cancer, breast cancer, CNS cancer, ovarian cancer, lung cancer, dyslipidemia, inflammatory diseases, inflammatory bowel disease, and arthritis .
Cat. No.: HY-101212R
CAS No.: 1070790-89-4
Synonyms: CYC065 (Standard)
Target:
Research Areas:
Fadraciclib (Standard) is the analytical standard of Fadraciclib (HY-101212). This product is intended for research and analytical applications. Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50s of 5 and 26 nM, respectively .
Cat. No.: HY-101212A
Target:
Research Areas:
(2S,3R)-Fadraciclib is the 2S,3R isomer of Fadraciclib (HY-101212). Fadraciclib is an orally potent ATP-competitive CDK2/CDK9 kinase inhibitor with IC50 values of 5 and 26 nM, respectively .
Cat. No.: HY-168897
CAS No.: 902959-52-8
Research Areas:
LC3B ligand 1 is a ligand for the target protein of PROTAC and can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .
Cat. No.: HY-W247437
CAS No.: 1472731-41-1
Target:
Research Areas:
E3 ligase Ligand 56 is the ligand for E3 ligase Cereblon and can be used for syntheisis of PROTAC CDK9 degrader-11 (HY-170978) .
Cat. No.: HY-130514
CAS No.: 327081-00-5
SMAPP1 is an activator of protein phosphatase-1 (PP1). SMAPP1 increases phosphorylation of CDK9’s Ser90 and Thr186 residues, but not Ser175. SMAPP1 induces HIV-1 replication, upregulates HIV-1 transcription that led to the reactivation of latent HIV-1 provirus .
Cat. No.: HY-133698
CAS No.: 2914920-52-6
Research Areas:
Lenalidomide-O-C7-COOH is an E3 ligase ligand-linker conjugate that can be used for the synthesis of PROTAC CDK9 degrader-14 (HY-133617).
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
